Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside

Figure 5

Cumulative incidence of treatment failure in 44 consecutive patients, receiving Imatinib for steroid-refractory cGVHD (Olivieri et al. [109]).